

Asthma

A study to find out how safe is it to give people with asthma a new medicine called MTPS9579A

Trial Status
Completed

Trial Runs In
1 Country

Trial Identifier
GA41003

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A phase 1c, multicenter, randomized, observer-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of a single dose of MTPS9579A in patients with asthma requiring inhaled corticosteroids and a second controller

Trial Summary:

This clinical trial was done to study a new medicine (MTPS9579A) for the treatment of asthma, to find out if it was safe for people with asthma. Other information researchers wanted to know included the concentration of MTPS9579A in the body after dosing, whether MTPS9579A was effective, and if the body made antibodies when exposed to MTPS9579A. Twenty-seven people who had asthma took part in this study at six study centers in one country.

Genentech, Inc., USA. (Part of F. Hoffmann-La Roche Ltd., Switzerland).
Sponsor

Phase 1c
Phase

GA41003
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
18 to 65 years

Healthy Volunteers
No

People with asthma requiring inhaled corticosteroids and a second controller were enrolled at six study sites in one country to evaluate the safety and tolerability of MTPS9579A, an antibody drug against tryptase. Twenty-seven participants completed the study and

ForPatients

by Roche

comprised the safety-evaluable population. This was a Phase 1c, multicenter, randomized, observer-blinded, placebo-controlled study. Results showed MTPS9579A to be tolerable with no drug-related serious side effects or drug-related non-serious side effects. The Sponsor is no longer developing MTPS9579A for asthma. This decision had nothing to do with the safety of the medicine.